Skip to content
Triclabendazole
Egaten (triclabendazole) is a small molecule pharmaceutical. Triclabendazole was first approved as Egaten on 2019-02-13. It is used to treat fascioliasis in the USA.
Download report
Favorite
Novartis Pharmaceuticals
FDA Novel Drug Approvals 2019
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
digestive system diseasesD004066
Trade Name
FDA
EMA
Egaten
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Triclabendazole
Tradename
Company
Number
Date
Products
EGATENNovartisN-208711 RX2019-02-13
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
egatenNew Drug Application2020-12-11
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
fascioliasisEFO_1001324D005211B66.3
Agency Specific
FDA
EMA
Expiration
Code
TRICLABENDAZOLE, EGATEN, NOVARTIS
2026-02-13ODE-228
2024-02-13NCE
Patent Expiration
No data
ATC Codes
P: Antiparasitic products, insecticides and repellents
— P02: Anthelmintics
— P02B: Antitrematodals
— P02BX: Other antitrematodal agents in atc
— P02BX04: Triclabendazole
HCPCS
No data
Clinical
Clinical Trials
2 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
FascioliasisD005211EFO_1001324B66.3———1—1
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Parasitic diseasesD010272EFO_0001067B88————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTRICLABENDAZOLE
INNtriclabendazole
Description
6-chloro-5-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzimidazole is an aromatic ether.
Classification
Small molecule
Drug classantithelmintics (tibendazole type)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1
Identifiers
PDB—
CAS-ID68786-66-3
RxCUI2118525
ChEMBL IDCHEMBL1086440
ChEBI ID—
PubChem CID50248
DrugBankDB12245
UNII ID4784C8E03O (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 937 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
34,356 adverse events reported
View more details